Experimental drug aims to fix Bone-Weakening phosphate problem in rare disease
NCT ID NCT05509595
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a drug called burosumab in 12 people with fibrous dysplasia who also had low blood phosphate, which can make bones weaker. Participants injected the drug at home once or twice a month for 48 weeks. The main goal was to see if the drug could raise phosphate levels to a normal range. Researchers also monitored side effects and bone health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
burosumab (a lab-made antibody that blocks FGF23, given as a shot under the skin)
What this could lead to
If it works, this could point toward a treatment that strengthens bones in people with fibrous dysplasia who have low phosphate levels.
What could go wrong
This is a very small, early-phase study (12 people) with no control group, so results may not apply to everyone. The drug may not improve bone symptoms or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROUS DYSPLASIA OF BONE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States